Ibrutinib belongs to a class of drugs are known as kinase inhibitors and is used to treat certain cancers, such as mantle cell lymphoma or marginal zone lymphoma, chronic lymphocytic leukemia/small lymphocytic lymphoma, and Waldenstrom's macroglobulinemia.
The drug will be manufactured at the group’s formulation manufacturing facility at the SEZ, Ahmedabad.
The group now has 319 approvals and has so far filed over 400 ANDAs since the commencement of the
filing process in FY 2003-04.
On Sensex, Cadila finished at Rs622 per piece flat compared to the previous closing.